Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab + Brentuximab Vedotin in CD30+ Non-Hodgkin Lymphomas
NCT02581631Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Feb 2016
- Primary completion
- Jan 2020
- Modality
- Monoclonal Antibodies
- Countries
- 6
01
Overview
A Phase 2 trial of nivolumab in diffuse large B-cell lymphoma (DLBCL), peripheral T-cell lymphoma (PTCL), cutaneous T-cell lymphoma (CTCL), primary mediastinal large B-cell lymphoma (PMBCL), mediastinal gray zone lymphoma (MGZL), sponsored by Bristol Myers Squibb. Started Feb 2016; status: completed.
02
Drugs
03
Conditions
diffuse large B-cell lymphoma (DLBCL)peripheral T-cell lymphoma (PTCL)cutaneous T-cell lymphoma (CTCL)primary mediastinal large B-cell lymphoma (PMBCL)mediastinal gray zone lymphoma (MGZL)
Beyond the preview
Go deeper on NCT02581631.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02581631.